Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells

Yi Ping Shih, Yoshikazu Takada, Su Hao Lo

研究成果: 雜誌貢獻文章同行評審

21 引文 斯高帕斯(Scopus)


Deleted in liver cancer 1 (DLC1) is a GTPase-activating protein (GAP) domain containing tumor suppressor that localizes to focal adhesions. In cancer cells, loss of DLC1 is known to enhance cancer cell migration. However, the role of DLC1 in normal cell migration has not been well studied. Here, we show that silencing of DLC1 (shDLC1) in normal prostate epithelial cells reduces cell migration in both Transwell and wound-healing assays. This migration defect is mainly due to upregulation of plasminogen activator inhibitor 1 (PAI-1). Silencing of PAI-1 rescues the shDLC1-reduced migration phenotype. Reexpression of DLC1 suppresses PAI-1 and restores the migration defect as well. In contrast, DLC1-K714E (GAP inactive) mutant neither decreases the PAI-1 level nor rescues the shDLC1 migration defect. Interestingly, DLC1-Y442F (tensin-binding and focal adhesion-localizing defective) mutant is able to suppress PAI-1 expression but does not restore the migration defect. Furthermore, PAI- 1 upregulation in shDLC1 cells is EGFR-MEK pathway dependent and is able to promote in vitro angiogenesis. Together, our results show that at least the following two new mechanisms are involved in DLC1-mediated normal cell migration: (i) DLC1 modulates the expression of PAI-1, which is a negative regulator for cell migration, in a GAP domain and EGFR-MEK-dependent manner and (ii) Independent of PAI-1, the interaction of DLC1 with tensin members positively regulates cell migration.

頁(從 - 到)34-39
期刊Molecular Cancer Research
出版狀態已發佈 - 1月 2012

ASJC Scopus subject areas

  • 分子生物學
  • 腫瘤科
  • 癌症研究


深入研究「Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells」主題。共同形成了獨特的指紋。